RSS   Newsletter   Contact   Advertise with us
Post Online Media
Post Online Media Magazine

Purdue Pharma appoints Marcelo Bigal as CMO

Share on Twitter Share on LinkedIn
Staff Writer | Stamford, Conn., USA |
Marcelo BigalPurdue Pharma, a pharmaceutical company, announced that Marcelo Bigal has been appointed chief medical officer.
Dr. Bigal brings more than 12 years of pharmaceutical experience spanning research and development, clinical operations and innovations, and scientific affairs.

Dr. Bigal comes to Purdue from Teva Pharmaceuticals, where he most recently served as Chief Scientific Officer for the specialty organization.

Prior to that he served as CMO and Head of the Clinical Development organization.

Before joining Teva, Dr. Bigal was CMO at Labrys Biologics, Inc., leading the team responsible for the development of fremanezumab, a humanized monoclonal antibody against CGRP, a potential anti-migraine and pain target.

Prior to his work in the pharmaceutical industry, Dr. Bigal was a faculty member at the Albert Einstein College of Medicine, Department of Neurology, as well as the Director of Research at New England Center for Headache, Stamford, Connecticut and Director of Research at Montefiore Headache Center, Bronx, New York.

Dr. Bigal has received prestigious awards, including the American Academy of Neurology Harold-Wolff John Graham Award for outstanding achievements in pain research.

He has published more than 310 peer-reviewed articles in indexed journals, edited six books and authored or co-authored 35 book chapters.

Dr. Bigal holds a Medical Doctorate degree from the College of Medicine at the University of São Paulo, Brazil, where he also obtained a Masters in Science and a PhD in Neurosciences.

He completed his post-doctoral research at the New England Center for Headache in Stamford, Conn.


POST Online Media Contact